HOTH•prnewswire•
Hoth Therapeutics Secures Major International Patent Milestone for HT-KIT Cancer Program, Strengthening Global Oncology IP Position
Summary
Chinese Patent Approved Covering HT-KIT Technology Designed to Induce Cancer Cell Apoptosis, Expanding Protection in One of the World's Largest Oncology Markets NEW YORK, Jan. 21, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on January 21, 2026 by prnewswire